About MMVSola Predictor
Version 1.7.3
Description
MMVSola Predictor is an R Shiny web application for pharmacokinetic (PK)
prediction of malaria drug candidates. It predicts human clearance from
in-vitro data (hepatocytes, microsomes) and in-vivo animal data via IVIVE
(in vitro–in vivo extrapolation), and simulates PK/PD profiles to estimate
efficacious doses for oral treatment and long-acting injectable (LAI)
chemoprevention.
The app is developed by
Medicines for Malaria Venture (MMV)
to support early-stage decision-making for antimalarial drug candidates.
Release Notes — v1.7.3
Bug fixes
-
User Guide equations rendered correctly on HTTPS:
Mathematical equations in the User Guide tab now render properly when
accessing the app via the public HTTPS URL. The fix switches MathJax from
the RStudio CDN (blocked by the server Content Security Policy) to
MathJax 3 via cdn.jsdelivr.net, which is on the allowlist.
-
User Guide scroll position preserved across tab switches:
Navigating away from the User Guide tab and returning no longer resets
the scroll position to the top. The iframe is now only reloaded when the
underlying documentation file changes on disk.
Release Notes — v1.7.2
New features
-
LAI chemoprevention sub-tab:
New Oral and LAI sub-tabs replace the previous single-panel Prediction view.
The LAI tab predicts doses for 90-day and 180-day coverage using fast and slow
Ka scenarios and both in-vitro and SCID EC50 sources.
-
Side-by-side PK/PD plots with interactive legend:
Each sub-tab shows two plots — in-vitro EC50-predicted doses on the left,
SCID EC50-predicted doses on the right — with checkboxes to toggle individual
curves. A merged single-plot view is available via a toggle button.
-
tMIC coverage segments on plots:
Each checked dose row overlays a segment showing the onset and duration of
MIC coverage with a dose-matched label (e.g. "28.1 d").
-
6 independent user dose inputs in Table 3:
Each Dose column (2 in Oral, 4 in LAI) has its own editable numeric input,
replacing the shared Simulated Dose parameter.
-
Dynamic plot panel titles:
The merged plot title reflects which EC50 sources contribute visible
predicted doses.
-
User Guide tab:
A comprehensive in-app user guide covering all major workflows, with
annotated screenshots and step-by-step instructions.
-
About tab:
New tab summarising the app description, release notes, and contact
information.
-
Redesigned Report tab and updated Excel report:
The Report tab has been redesigned for clarity. The Excel report now
includes separate sheets for Oral and LAI predictions.
Enhancements
-
Hepatic extraction ratio (E
H
) in Oral Table 1:
E
H
is shown in Predicted Human PK Parameters, making the
Fa → Fabs
1
correction transparent.
-
Fa tooltip:
An info icon on Fraction Absorbed (Fa) inputs explains the distinction between
oral (first-pass corrected) and LAI (bioavailability directly).
-
Y-axis anchored to MIC:
Both Oral and LAI plots anchor the y-axis to MIC/100 – 100×MIC.
-
Improved fu prediction:
Updated to MMVhuPKpred v0.1.14 with rules for fu prediction from available
inputs; a new action button generates a table of default value predictions.
-
Default value dependency graph:
A new collapsible group in the left-hand menu shows an interactive dependency
graph illustrating which inputs drive each predicted fu value.
-
Rules for fractions unbound:
Missing fu values (hepatocyte and microsome fu per species) are derived from
available measurements following an agreed hierarchy.
-
Reference human body weight updated to 55 kg:
Changed from 60 kg for consistency with clinical trial datasets for
African adults. Note: this affects oral predicted doses relative to
previous versions.
-
Separate fraction absorbed (Fa) parameters for Oral and LAI:
Fa is now defined independently for each route —
Oral (default 1.0), LAI fast (default 0.8), LAI slow (default 0.8).
-
Separate absorption rate (Ka) parameters for Oral and LAI:
Ka is now defined independently for each route —
Oral (default 1.0 1/h), LAI fast (default 2.98×10⁻³ 1/h,
based on medroxyprogesterone acetate), LAI slow (default 2.08×10⁻⁴ 1/h,
based on levonorgestrel butanoate).
Bug fixes
-
12-log kill PD curve floor:
Parasitemia curve now correctly stays at the minimum value after parasite
clearance without bouncing back.
-
Checkbox synchronisation:
Per-compound checkbox state is managed via a dedicated MMVshiny input type;
duplicate DOM IDs in the LAI tab resolved.
-
Test suite updated:
Tests redesigned with shinytest2; reference report files updated to match
current output format.
Release Notes — v1.6.0
- 21-day and 28-day > MIC dose predictions added to the Predict Dose
dialog and Excel report.
- SCID EC50 and SCID Hill included as user inputs for SCID-based dose
prediction.
- Absorption rate (Ka) made a user-editable input parameter
(previously fixed at 1.0 /h).
- Dual renv lock files (renv.R3.lock / renv.R4.lock) for R 3 and R 4
compatibility.
- Default value source shown in User Inputs report sheet.
Contact
For questions or feedback, please contact:
Medicines for Malaria Venture (MMV)
Route de Pré-Bois 20, 1215 Geneva 15, Switzerland
www.mmv.org